Clinical Trial

Safety and Efficacy of FAP iCDC in Acute Myocardial Infarction With Cardiogenic Shock

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To study the safety and efficacy of fibroblast activation protein (FAP)-targeted allogeneic immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of acute myocardial infarction with cardiogenic shock and provide a new method for the treatment of acute myocardial infarction with cardiogenic shock.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07380659
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Cardiogenic Shock, Cardiogenic Shock Post Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction
Enrollment 18 participants
Start Date 2026-01-20
Primary Completion 2027-01-30 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-02-02